ZYLOXTB (02190) surged over 5% intraday in Hong Kong trading. As of press time, the stock had climbed 3.76% to HK$23.2, with a turnover of HK$15.3907 million. Adding to the positive momentum, earlier this month, ZHUANG MEDICAL—an affiliate of ZYLOXTB—secured National Medical Products Administration (NMPA) approval for its independently developed ZYLOX KINGKONG™ Peripheral High-Pressure Balloon Dilatation Catheter. This innovative device is indicated for percutaneous transluminal angioplasty in peripheral blood vessels, encompassing upper extremity, renal, iliac, and infrainguinal vessels. It also addresses stenosis in autologous or synthetic arteriovenous fistulas used for dialysis and supports post-dilation of stents and covered stents within the peripheral vascular system. CSC Financial previously noted that ZYLOXTB stands as a leader in China’s peripheral and neuro-interventional sectors, boasting a rich product pipeline with multiple innovative offerings anticipated to gain regulatory clearance sequentially. Against the backdrop of potential benefits from centralized procurement and accelerated import substitution for select products, the company’s core business is set to maintain rapid growth. In 2024, ZYLOXTB achieved its first-ever profit turnaround. With expanding sales scale and ongoing improvements in operational efficiency, its profitability is expected to keep rising. Financially robust, the company held RMB2.53 billion in cash as of the first half of 2025. It plans to ramp up investments in R&D and academic promotion, while exploring opportunities for strategic mergers, acquisitions, and external collaborations to further solidify its industry-leading position.